HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Avon Q2

This article was originally published in The Rose Sheet

Executive Summary

Chinese government offers verbal permission for Avon to roll out a direct-sell test program in the country, CEO Andrea Jung announces during a Q2 analyst call July 28. Company is awaiting a written agreement, she adds. Avon expects the Chinese government will allow firm to resume direct selling in early 2005. Company currently views China as its largest long-term growth opportunity; sales in the country increased over 60% in Q2, direct-seller reports. In the U.S., Avon sales grew 3% to $545.8 mil., with beauty products up 6%. Worldwide skin care sales grew 18%, and color cosmetics were up 15%, driven by the Beyond Color franchise. Personal care revenue jumped 23% on the strength of hair care and bath products, while fragrance sales were up 12%. Consolidated sales were up 13% to $1.84 bil., and net income soared 35.5% to $232.3 mil...

Latest Headlines
See All
UsernamePublicRestriction

Register

RS012330

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel